First Patient Expected to be Dosed Next Week with Intranasal Foralumab PET Scan Shows Presence of Untreated Neuroinflammation ...
A laboratory study out of Roswell Park Comprehensive Cancer Center outlines a new way to boost the effectiveness of chimeric ...
When cells can’t destroy damaged proteins, a hidden backup system led by NRF1 steps in to prevent toxic buildup.
Early-life viral infection programs immune cells to hijack allergy-associated maternal antibodies, driving allergy risk later ...
Cancer immunotherapy has transformed cancer treatment, yet many patients experience limited or short-lived responses due to ...
Discover why CLLS is a top speculative Buy, with promising CAR-T therapies, strong big pharma partnerships, and attractive ...
Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor (CAR) T cell that ...
Automated TCR-T production streamlines personalized immunotherapy, reducing patient burden and improving engineered T cell quality.
CHICAGO — Rosnilimab, a novel pathogenic T-cell depleting drug, met its primary endpoint of changes in DAS28 C-reactive ...
Learn how Logic-gated DARPins work to activate T cells selectively in solid tumours, enhancing therapeutic outcomes.
Patients with advanced marginal zone lymphoma (MZL) now have a CAR T-cell therapy with the FDA approval of lisocabtagene ...
This valuable work investigates the role of protein N-glycosylation in regulating T-cell activation and function and suggests that B4GALT1 is a potential target for tumor immunotherapy. The strength ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback